- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Xanthelasma Palpebrarum Not Linked to Increased Cardiovascular or Dyslipidemia Risk: Study
Research has established that xanthelasma palpebrarum (XP), which is associated with yellowish cholesterol deposits on the eyelids, does not significantly contribute to the incidence of dyslipidemia and cardiovascular disease (CVD). A recent study was published in the journal Ophthalmology conducted by Lustig-Barzelay and colleagues..
This study was designed to establish a hypothesis to identify an association between xanthelasma palpebrarum and dyslipidemia, cardiovascular disease, and other systemic conditions within a large population.
Case-control study was carried out at a single tertiary care center in the medical records of 2001 to 2020. Available records were reviewed on the grounds of ophthalmic evaluations, results from blood tests, and diagnoses for systemic conditions. The study group consisted of patients diagnosed with XP in at least one eye, while a control group without XP was established and matched by age and sex at a ratio of 10:1 for the purposes of robust statistical comparisons between the two groups. The main outcome measures were associations of XP with dyslipidemia and cardiovascular disease with an emphasis on comparing lipid profiles and use of medications between the groups.
• The database consisted of 35,452 individuals with an average age of 52.2 ± 12.2 years. Of the total number, 24,287 patients (69%) were males.
• Of these, 203 patients had a diagnosis of XP, while there were 2,030 matched controls included in the study population.
• The prevalence of dyslipidemia was not significantly different between groups, 42% in XP compared with 46% in controls (P = 0.29).
• The use of lipid-lowering agents, that is, statins and fibrates, was nearly the same for both study groups ( P = 0.88).
• Lipid profiles, including total cholesterol, HDL, LDL, and triglyceride levels, were similar in XP patients compared with controls. As an example, median total cholesterol was 192 (XP) vs. 187 (controls) (P = 0.093); LDL was 125 (XP) vs. 120 (controls) (P = 0.17).
• The rates of CVDs were similar between the groups, though 8.9% of XP patients had a history of CVD as compared to 10% controls (P = 0.56).
• Other systemic conditions were also similar between the groups and include hypertension, with 23% of XP and 24% controls. Diabetes mellitus was found in 10% XP as opposed to 14% controls, and cerebrovascular accidents with 1% XP versus 1.3% controls (P>0.05).
XP in itself is not an indicator of an increased incidence of dyslipidemia and cardiovascular disease, as was observed in this large population study. However, based on the present results, the presence of XP should by itself not be used as a marker for heightened cardiovascular or lipid-related risk. This study points out the necessity for further research with respect to systemic relevance and supports a more conservative interpretation of its clinical significance in cardiovascular and lipid health.
Reference:
Lustig-Barzelay, Y., Kapelushnik, N., Goldshtein, I., Leshno, A., Segev, S., Ben-Simon, G. J., & Landau-Prat, D. (2024). Association between xanthelasma palpebrarum with cardiovascular risk and dyslipidemia. Ophthalmology. https://doi.org/10.1016/j.ophtha.2024.07.033
Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751